Rexahn Pharmaceuticals is a development-stage biopharmaceutical company focused on the development of cures for cancer to patients worldwide. The company’s pipeline features one drug candidate in phase 2 clinical trials. RNN also has several other drug candidates in pre-clinical development. RNN has two renal cell carcinoma (CNS) candidates: Serdaxin for depression and neurodegenerative diseases; and Zoraxel, an erectile dysfunction (ED) and sexual dysfunction drug. For more information, visit the company’s Web site: http://www.rexahn.com
Let us hear your thoughts below: